A double-blind, randomized, placebo-controlled, dose-finding phase II study to assess the efficacy and safety of pasireotide s.c. in patients with Post-Bariatric Hypoglycaemia
SOM230-RECAG-CL-0576
Phase 2 other active
Quick answer
A double-blind, randomized, placebo-controlled, dose-finding phase II study to assess the efficacy and safety of pasireotide s.c. in patients with Post-Bariatric Hypoglycaemia for Post-Bariatric Hypoglycaemia is a Phase 2 program (other) at Recordati Ireland with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Recordati Ireland
- Indication
- Post-Bariatric Hypoglycaemia
- Phase
- Phase 2
- Modality
- other
- Status
- active